Overview

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Treatments:
Empagliflozin